R
Relmada Therapeutics, Inc. (RLMD)
NCM – Real Time Price. Currency in USD
7.45
+0.09 (1.22%)
At close: May 12, 2026, 4:00 PM EDT
7.45
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
7.45
+0.09 (1.22%)
At close: May 12, 2026, 4:00 PM EDT
7.45
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
| Name | Position |
|---|---|
| Dr. Andrew Cutler | Senior Clinical Development Advisor |
| Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer of Urology |
| Dr. Richard M. Mangano Ph.D. | Consultant |
| Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director |
| Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer |
| Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer |
| Mr. Paul E. Kelly M.B.A. | COO & Director |
| Ms. Gina DiGuglielmo | VP & Head of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-04-17 | DEFA14A | ea0273288-04.htm |
| 2026-04-17 | DEF 14A | ea0273288-03.htm |
| 2026-04-07 | CORRESP | filename1.htm |
| 2026-04-06 | PRE 14A | ea0273288-01.htm |
| 2026-04-03 | S-3 | ea0282915-s3_relmada.htm |
| 2026-03-20 | 8-K | ea0282688-8k_relmada.htm |
| 2026-03-19 | 10-K | ea0273255-10k_relmada.htm |
| 2026-03-09 | 8-K | ea0280436-8k_relmada.htm |
| 2025-12-15 | 8-K | ea0269660-8k_relmada.htm |
| 2025-11-13 | 8-K | ea026563001-8k_relmada.htm |